Actively Recruiting
Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
Led by University of Bonn · Updated on 2025-04-10
100
Participants Needed
1
Research Sites
212 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The GCAIO study is an innovative, multimodal research initiative designed to enhance the understanding, diagnosis, and management of giant cell arteritis (GCA) and frequently associated polymyalgia rheumatica (PMR). This longitudinal study aims to dissect the complex immunological landscape and systemic manifestations of these conditions through a combination of diagnostic imaging and detailed immunological profiling. The study focuses on three primary objectives: (1) Identifying and analyzing cytokine profiles and immune cell phenotypes, employing techniques like flow cytometry, enzyme-linked immunosorbent assays (ELISA), and next-generation sequencing to predict disease activity and therapeutic responses. (2) Advancing diagnostic and monitoring capabilities through the application of novel and established imaging technologies, including MRI, optical coherence tomography angiography (OCTA), and ultrasound. These modalities aim to improve the detection of neuro-ophthalmological, cardiac, and aortic complications in GCA, potentially offering more precise monitoring and earlier diagnosis. (3) Enhancing the understanding of PMR within the context of GCA by exploring specific biomarkers and advanced imaging to refine diagnostic accuracy and treatment strategies, thus improving patient outcomes.
CONDITIONS
Official Title
Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be 18 years or older and provide written informed consent.
- Diagnosis of giant cell arteritis or polymyalgia rheumatica confirmed by a physician using expanded ACR-EULAR classification criteria.
- Participants must be newly diagnosed or have had a disease flare within the last three days.
You will not qualify if you...
- Severe kidney failure with a glomerular filtration rate less than 30 mL/min.
- Presence of medical conditions other than GCA or PMR requiring treatment with glucocorticoids.
- Having other inflammatory rheumatic diseases.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Bonn
Bonn, North Rhine-Westphalia, Germany, 53127
Actively Recruiting
Research Team
S
Simon M. Petzinna, Dr. med.
CONTACT
V
Valentin S. Schäfer, Univ. Prof.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here